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Chronic obstructive pulmonary disease is associated 
with a higher level of serum uric acid. 
A systematic review and meta-analysis
Abstract
Introduction: Recent studies have suggested that patients with chronic obstructive pulmonary disease (COPD) may have a higher 
level of serum uric acid compared with individuals without COPD, although the data are still limited. The current systematic review 
and meta-analysis was conducted to summarize all available data.
Material and methods: A systematic review was performed using the MEDLINE and EMBASE databases from their inception 
to July 2019. Studies that were eligible for the meta-analysis must have consisted of two groups of participants, patients with 
COPD and individuals without COPD. The eligible studies must have reported either mean or median level of serum uric acid and 
its standard deviation (SD) or interquartile range of participants in both groups. Mean serum uric acid level and SD of participants 
in both groups were extracted from each study and the mean difference (MD) was calculated. Pooled MD was then computed 
by combining MDs of each study using random effects model.
Results: A total of eight studies with 1,612 participants met the eligibility criteria and were included in the data analysis. The 
serum uric acid level among patients with COPD was significantly higher than individuals without COPD with the pooled MD of 
0.91 mg/dL (95% CI: 0.45–1.38; I2 = 89%).
Conclusions: The current study found a significantly higher level of serum uric acid among patients with COPD than individuals 
without COPD.
Key words: chronic obstructive pulmonary disease, serum uric acid, meta-analysis
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Introduction 
Chronic obstructive pulmonary disease 
(COPD) is one of the most common pulmonary 
disorders worldwide. The disease is character-
ized by persistent respiratory symptoms due 
to airflow limitation. Airway and/or alveolar 
abnormalities of COPD are usually caused by 
significant exposure to noxious particles or gases 
[1]. COPD is currently the fourth leading cause 
of death globally according to the World Health 
Organization (WHO) and is predicted to become 
the third leading cause of mortality by 2030 [2]. 
Mechanisms that lead to airway destruction in-
clude oxidant/antioxidant imbalance, unopposed 
protease activity, inflammation, autoimmunity 
and enhanced apoptosis [3–6].
Hyperuricemia is a common metabolic ab-
normality that can lead to various clinical phe-
notypes, ranging from asymptomatic incidental 
laboratory abnormality to acute gouty arthritis 
and urate nephropathy [7–8]. Recent studies have 
suggested that serum uric acid level could be 
used as a marker of tissue hypoxia, particularly 
among patients with pulmonary diseases [9–10]. 
The increased level of serum uric acid is thought 
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to be a consequence of increased purine catabo-
lism in the presence of tissue hypoxia [11]. The 
current systematic review and meta-analysis was 
conducted to compare serum uric acid level be-
tween patients with COPD, a common hypoxemic 
disorder, and individuals without COPD [12–19].
Material and methods
Search strategy
Three investigators (P.W., P.R., N.C.) inde-
pendently searched for published studies indexed 
in EMBASE and MEDLINE from their inception 
to July 2019. Search terms were compiled from 
terms related to COPD and uric acid. The detailed 
search strategy is provided in the supplementary 
data 1. No language limitation was applied. Refer-
ences of the included studies were also manually 
reviewed for additional eligible studies. This 
study was undertaken in accordance with the 
Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement, which 
is available as supplementary data 2.
Inclusion criteria
Studies that were eligible to be included into 
the meta-analysis must have consisted of two 
groups of participants, patients with COPD and 
individuals without COPD, and have reported 
either mean or median level of serum uric acid 
of participants in both groups and its standard 
deviation (SD), standard error of the mean (SE) 
or interquartile range, regardless of study design.
Study eligibility was independently deter-
mined by the three investigators (P.W., P.R., N.C.). 
Different opinions were resolved by conference 
with the senior investigator (P.U.). The quality 
of each study was jointly evaluated by all in-
vestigators using the Newcastle-Ottawa quality 
assessment scale for cohort studies [20] and the 
modified Newcastle-Ottawa quality assessment 
scale as described by Herzog et al. for cross-sec-
tional studies [21].
Data extraction
A standardized data collection form was used 
to extract the following information: last name 
of the first author, country where the study was 
conducted, study design, year of publication, total 
number of participants, recruitment of patients 
with COPD and individuals without COPD, average 
age of participants, percentage of females and meth-
ods used to diagnose COPD. This data extraction 
was independently performed by the same three in-
vestigators (P.W., P.R., N.C.) to minimize error. Any 
discrepancies found in the case record forms were 
resolved by referring back to the original articles.
Statistical analysis 
Mean serum uric acid level and SD of partic-
ipants in both groups were extracted from each 
study and the mean difference (MD) was calculat-
ed. Pooled MD was then computed by combining 
MDs of each study using random effects model. 
If the study provided median and interquartile 
range instead of mean and SD, median would 
be used as an estimate for mean and SD would 
be estimated from interquartile range divided 
by 1.35. The heterogeneity of the MDs across 
the included studies was quantified using the Q 
statistic, which is complemented with I2 statis-
tics. A value of I2 of 0–25% indicates insignificant 
heterogeneity, 26–50% low heterogeneity, 51–75% 
moderate heterogeneity and 76–100% high het-
erogeneity [22]. Visual inspection of funnel plots 
was used to assess for the presence of publication 
bias. Data analysis was performed using Review 
Manager 5.3 software from the Cochrane Collab-
oration (London, United Kingdom).
Results
The systematic search identified 526 poten-
tially relevant articles (412 articles from EMBASE 
and 114 articles from MEDLINE). After the ex-
clusion of 100 duplicated articles, 426 articles 
underwent title and abstract review. A total of 
406 articles were excluded at this stage as they 
clearly did not fulfill the eligibility criteria based 
on the type of article, study design, participants 
and outcome of interest. A total of 20 articles 
were retrieved for full-length article review and 
12 articles were excluded at this stage as they did 
not report the level of serum uric acid among par-
ticipants with and without COPD. Finally, eight 
studies [12–19] with 1,612 participants were eligi-
ble for the meta-analysis. The literature retrieval, 
review and selection process are shown in Figure 
1. The characteristics of the included studies and 
their quality assessment are described in Table 1.
Serum uric acid level among patients
with COPD versus individuals without COPD
The pooled analysis found a significantly 
increased serum uric acid level among patients 
with COPD compared with individuals without 
COPD with the pooled MD of 0.91 mg/dL (95% 
CI: 0.45–1.38). The between-study heterogeneity 
was high with an I2 of 89%. Figure 2 demonstrated 
the forest plot of the included studies.
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Figure 1. Literature review process
Evaluation for publication bias
Funnel plot was used to evaluate for the 
presence of publication bias as shown in Figure 
3. The plot was relatively asymmetric and may 
suggest the presence of publication bias.
Sensitivity analysis
A sensitivity analysis was conducted to ex-
clude two studies [17–18] that reported median 
and interquartile range and, thus, mean and SD 
had to be approximated using the technique de-
scribed under Methods. Exclusion of these two 
studies from the pooled analysis only slightly 
increased pooled MD to 1.16 and remained sta-
tistically significant (95% CI: 0.57–1.75; I2 88%), 
suggesting that the approximation did not have 
a substantial impact on the pooled result (sup-
plementary data 3).
Discussion
The current study is the first systematic 
review and meta-analysis that summarized data 
from all available studies that compared the level 
of serum uric acid among patients with COPD 
versus individuals without COPD. We found that, 
on average, patients with COPD had a higher 
level of serum uric acid level than individuals 
without COPD with the difference of almost 
1 mg/dL, which is approximately the same as the 
magnitude of uric acid reduction clinicians can 
expect from patients with gout/hyperuricemia 
who follow low-purine diet [23]. This observation 
may reinforce the hypothesis that tissue hypoxia 
can increase the rate of purine catabolism. In fact, 
in vitro and animal studies have indicated that 
hypoxic state can reversibly enhance oxidation 
of xanthine dehydrogenase into xanthine oxidase 
[12, 24–26]. Since significant number of patients 
with COPD has systemic hypoxia at rest or during 
acute exacerbation as a result of decreased oxygen 
diffusion capacity and alveolar hypoventilation, 
higher xanthine oxidase activity and increased 
serum uric acid level could be expected.
Another possible explanation is associated 
with an increased oxidative stress, which is 
a prominent feature of COPD [27]. Uric acid is 
classified as a low molecular weight water soluble 
antioxidant [12] that takes part in protecting the 
lungs from oxidative stress by inhibiting lipid per-
oxidation and scavenging reactive oxygen species 
and reactive nitrogen species [28]. Therefore, it is 
possible that the higher level of serum uric acid is 
a counter-response to a higher burden of oxidative 
stress among patients with COPD [3, 29].
Because of the observational nature of the 
included studies, it is also possible that the 
observed association between COPD and high-
er serum uric acid level is not causal with no 
direct mechanistic link. A recent systematic 
review found that metabolic syndrome is com-
mon among patients with COPD that is found 
in about one-third of them [30]. Since there is 
a strong association between insulin resistance, 
metabolic syndrome and hyperuricemia, [31] the 
observed higher level of serum uric acid level 
could be confounded by co-morbidities rather 
than COPD itself. 
The results of this systematic review and 
meta-analysis may suggest that patients with 
COPD could be at a higher risk of hyperuricemia 
and serum uric acid may be worth checking for 
patients with COPD who exhibit signs and symp-
toms of complications of hyperuricemia, such as 
acute arthritis and kidney stones.
Few limitations of this systematic review 
and meta-analysis should be noted. First, be-
tween-study heterogeneity was high in this anal-
ysis, suggesting that the results of the primary 
studies could be too heterogeneous to combine 
together. The difference in background popula-
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Figure 3. Funnel plot o1.1f the meta-analysis
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tions of patients with COPD was the most likely 
explanation for the variation. Second, funnel plot 
of this analysis was relatively asymmetric and 
may suggest the presence of publication bias in 
favor of studies that report positive results. Third, 
the quality of some included studies was fairly 
low as reflected by low Newcastle-Ottawa scores.
Conclusions
In conclusion, this study found a higher 
level of serum uric acid among patients with 
COPD. Tissue hypoxia and increased oxidative 
burden are the possible explanations as well as 
confounding effect of co-morbidities. 
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